Trial Profile
Medical Record Review and Data Abstraction for Pediatric, Adolescent and Pregnant Patients Treated With IV Zanamivir in the Relenza Compassionate Use Program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Zanamivir (Primary)
- Indications Influenza virus infections; Respiratory tract infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Aug 2011 Actual initiation date (Jul 2011) added as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 May 2011 New trial record